Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo

Movement Disorders

Volumn 25, Issue 11, 2010, Pages 1708-1714

  Menza, Matthew ^a,b   Dobkin, Roseanne DeFronzo ^a   Marin, Humberto ^a,b   Gara, Michael ^a,b   Bienfait, Karina ^a   Dicke, Allison ^a   Comella, Cynthia L ^c   Cantor, Charles ^d   Hyer, Lee ^e  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Insomnia; Parkinson's disease; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; ESZOPICLONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PLACEBO;

ADULT; AROUSAL; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SIDE EFFECT; SLEEP; SLEEP TIME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AZABICYCLO COMPOUNDS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PARKINSON DISEASE; PIPERAZINES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955788604     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23168     Document Type: Article

References (36)

1. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5:280-285.
2. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease: a self-reported, community- based survey. Sleep Med 2002;3:147-149.
3. Scaravelli T, Gasparoli E, Rinaldi F, Polesello G, Bracco F. Health related quality of life and sleep disorders in Parkinson's disease. Neurol Sci 2003;24:209-210.
4. Karlsen KH, Tanberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69:584-589.
5. Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson's disease and in their caregivers. Parkinsonism Relat Disord 2004;10:157-168.
6. Karlsen KH, Tanberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69:584-589.
7. Smith MC, Ellgring H, Oertel WH. Sleep disturbances in Parkinson's diseasepatientsandspouses.JAmGeriatrSoc1997;45:194-199.
8. Garcia-Borreguero D, Larrosa O, Bravo M. Parkinson's disease and sleep. Sleep Med Rev 2003;7:115-129.
9. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-899. (Pubitemid 28517665)
10. Rechtschaffen A, Kales A. Manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles: Brain Information Service/Brain Research Institute; 1968.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Bastien CH, Vallieres A, Morin CM. Validation of insomnia severity index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.
13. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 1997;12:805-814.
14. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease, Vol.2. Florham Park, NJ: Macmillan Health Care Information; 1987. p153-164.
15. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976.
16. Krupp LB, LaRocca NC, Muit-Nash J, et al. The fatigue severity scale applied to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
17. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
18. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
19. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982;5:183-194.
20. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease: a self-reported, community- based survey. Sleep Med 2002;3:147-149.
21. Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med 2001;63:49-55.
22. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep 1999;22:S379-S385.
23. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-968.
24. Krystal AD. Treating the health, quality of life, and functional impairments in insomnia. J Clin Sleep Med 2007;3:63-72.
25. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-899. (Pubitemid 28517665)
26. Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991;5:399-407.
27. Unruh ML, Redline S, An MW, et al. Subjective and objective sleep quality and aging in the sleep heart health study. J Sleep Res 2009;3:152-158.
28. Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med 1997;336:341-346.
29. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-968.
30. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633-1642.
31. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6:487-495. (Pubitemid 41671203)
32. Krystal AD, Walsh JK, Laska E, et al.. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799.
33. Lowe AD. Sleep in Parkinson's disease. J Psychosom Res 1998;6:613-617.
34. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26:261-282.
35. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trail. JAMA 1999;281:991-999.
36. Cicolin A, Lopiano L, Zibetti M, et al. Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med 2004;5:207-210. (Pubitemid 38351837)